NGS

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

MiLaboratories Introduces Platforma Bio: A Revolutionary UI-First Computational Biology Platform powered by AI

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Stem Cells, Software, Biotechnology, Health, Other Science, Science, Artificial Intelligence, Computational biology, Multimedia, NGS, Organization, Interest, UI, AI, Data analysis, Online shopping

MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .

Key Points: 
  • MiLaboratories, a leader in developing best-in-class software for immunological data analysis, proudly announces the official launch of Platforma.bio .
  • This groundbreaking computational biology platform, powered by AI large language models, is designed to significantly streamline, and simplify biological analysis, making it more accessible to researchers across various disciplines.
  • Platforma.bio stands out in the computational biology field with its unique, patent-pending engine that effectively identifies and eliminates redundant computations.
  • To introduce Platforma.bio to the research community, MiLaboratories will host a detailed webinar showcasing its features and practical applications.

Elegen Launches ENFINIA™ DNA Enhancement for Rapid Synthesis of Highly Complex DNA

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, SV40, Associate, GSK, NGS, RNA, DNA, EAP, Messenger, Cauliflower mosaic virus, Doctor of Philosophy, Lentivirus, Therapy, IRES, Access, Orbital, IVT, Vaccine

This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.

Key Points: 
  • This upgrade to ENFINIA DNA sets a new standard for DNA manufacturing, providing an industry-leading combination of speed, length, NGS-verified accuracy and complexity.
  • EAP partners received long and very complex DNA sequences that were either rejected by other suppliers or would have taken months to synthesize.
  • Elegen commercially launched ENFINIA DNA in Q1 2023 , delivering NGS-verified, linear DNA up to 7kb in 6 to 8 business days.
  • This latest enhancement of ENFINIA DNA to produce high-complexity DNA marks another step in the company’s mission to develop innovative solutions for DNA manufacturing, including even longer DNA, plasmid DNA and clinical-grade DNA production.

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Research, Pharmaceutical, Oncology, Health, Genetics, Other Health, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

Eaton delivers FAA-approved Boeing 737 Next Generation / 737 MAX oxygen sensor replacement to commercial aviation aftermarket

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Air, Engineering, Transport, Aerospace, Manufacturing, Machinery, Other Travel, Transportation, Travel, ASM, Environment, NGS, Boeing, Quality of life, OEM, Safety, MAX, Federal Aviation Administration, Airline

Eaton’s oxygen sensor is a form, fit and functional replacement for the OEM Boeing 737 NG / 737 MAX sensor.

Key Points: 
  • Eaton’s oxygen sensor is a form, fit and functional replacement for the OEM Boeing 737 NG / 737 MAX sensor.
  • In response to the market need for a more reliable oxygen sensor, Eaton’s replacement is designed from its proven high-performance commercial and military oxygen sensor that provides cost savings through increased reliability and time on wing.
  • The replacement Boeing 737 NG / 737 MAX oxygen sensor (part number 3270108-0101) complements Eaton’s existing highly reliable Boeing 737 NG / 737 MAX air separation module replacement for the same platform.
  • To learn more about Eaton’s NGS oxygen sensor and ASM, visit NGS oxygen sensor | Aerospace | Eaton .

Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, CE, Thermo Fisher Scientific, CDX, Patient, NGS, Bayer, Executive Committee, Neoplasm, Liquid biopsy, Pharmaceutical industry

Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.

Key Points: 
  • Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together.
  • These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.
  • Pairing this with Bayer’s growing precision oncology portfolio, we are well-positioned for the potential to help ensure that eligible patients can be quickly matched with the right treatment.”
    Financial terms of the cooperation were not disclosed.
  • *The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.

Genseq Selects Sapio LIMS to Power Best-in-Class Next-Generation Sequencing Services

Retrieved on: 
Monday, March 18, 2024
Software, Research, Professional Services, Pharmaceutical, Data Management, Apps, Applications, Technology, Health Technology, Data Analytics, Science, Biotechnology, Health, Other Science, Quality control, Genomics, Laboratory information management system, Communication, LIMS, NGS, AI, CAP, ELN, Al Ain Oasis, GxP, Fine chemical

Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.

Key Points: 
  • Founded in 2023, Genseq uses state-of-the-art sequencing platforms, including Novaseq, Nextseq, and Nextseq Dx, to ensure excellent quality and accuracy in sequencing data generation.
  • In addition to providing a full range of genomics, transcriptomics, and single-cell sequencing services, Genseq’s biobanking facility can accommodate more than 500,000 samples.
  • Genseq will use the advanced LIMS functionality from Sapio to track all aspects of sample management , including sample accessioning, storage, quality control, and aliquoting.
  • “Sapio is supporting Genseq in meeting its promise to clients, and we’re excited to partner with them as they grow their capabilities to meet demand.”

seqWell Launches First Assay-ready, 384-well Library Preparation Kit to Enable Ultra-high Throughput Plasmid and Synthetic Construct Sequencing

Retrieved on: 
Monday, March 18, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, Health Technology, Genetics, Entrepreneurship, Synthetic biology, NGS, Workflow, Plastic, Multimedia, Plasmid, DBTL

ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.

Key Points: 
  • ExpressPlex HT uses a 90-minute workflow in a single mastermix reaction to streamline NGS library preparation through massive multiplexing, thereby enabling lower cost, high throughput sequencing of plasmids, amplicons and other synthetic constructs used in synthetic biology.
  • View the full release here: https://www.businesswire.com/news/home/20240318055628/en/
    seqWell's ExpressPlex HT 384-well library prep kit is the first commercially available next-generation sequencing library preparation kit enabling multiplexing up to 6,144 samples in a pre-plated 384-well format.
  • (Graphic: Business Wire)
    “ExpressPlex HT was a natural step in broadening our portfolio of scalable, multiplex library preparation solutions,” said Jack Leonard, Chief Technology Officer at seqWell.
  • Massive multiplexing using 6,144 indices and a fully automated, 90-minute library preparation workflow enable 24-hour sample-to-answer turnaround for greater than 6,000 samples.

Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research

Retrieved on: 
Friday, March 15, 2024
Research, Medical Devices, Medical Supplies, Baby, Maternity, Genetics, Health Technology, Health, Consumer, Science, Quality control, SVP, Workflow, FACMG, NGS, Element, Database, Gene, Collection, RUO, Doctor of Philosophy

Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.

Key Points: 
  • Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.
  • “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn sequencing research and providing critical components necessary to be able to go from sample to result,” said Madhuri Hegde, PhD, FACMG, SVP and chief scientific officer, Revvity.
  • “We are accelerating the democratization of genomic sequencing by addressing the typical challenges faced by labs.”
    The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process.
  • The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants.

Global gRNA Market to Surpass USD 1.62 Billion by 2030 with Robust Growth in Next-Generation Sequencing and Genome Engineering Applications - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Growth, Gene editing, NGS, Research, RNA, Lead, Massive parallel sequencing, Guide, Good laboratory practice, IND, Medicine, Inde, Investment, CRISPR, USD, GLP, Pharmaceutical industry

The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.

Key Points: 
  • The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.
  • The latest market report on the global gRNA industry, now available for review, emphasizes the utility of products and custom gRNA synthesis services, and the ever-expanding realm of research applications.
  • Pharmaceutical and biotechnology companies are leveraging gRNA to pioneer advancements in precision medicine, positioning themselves as key end-users and market growth propellants.
  • The integration of advanced technologies and the discovery of novel applications are key to sustaining this growth momentum.